Literature DB >> 23344459

The pathogenetic role of IL-1β in severe epidermolysis bullosa simplex.

Verena Wally, Thomas Lettner, Patricia Peking, Doris Peckl-Schmid, Eva M Murauer, Stefan Hainzl, Helmut Hintner, Johann W Bauer.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23344459     DOI： 10.1038/jid.2013.31

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  14 in total

1.  Topical diacerein for epidermolysis bullosa: a randomized controlled pilot study.

Authors:  Verena Wally; Sophie Kitzmueller; Florian Lagler; Angelika Moder; Wolfgang Hitzl; Martin Wolkersdorfer; Peter Hofbauer; Thomas K Felder; Michael Dornauer; Anja Diem; Nora Eiler; Johann W Bauer
Journal:  Orphanet J Rare Dis       Date:  2013-05-07       Impact factor: 4.123

2.  Persistent release of IL-1s from skin is associated with systemic cardio-vascular disease, emaciation and systemic amyloidosis: the potential of anti-IL-1 therapy for systemic inflammatory diseases.

Authors:  Keiichi Yamanaka; Takehisa Nakanishi; Hiromitsu Saito; Junko Maruyama; Kenichi Isoda; Ayumu Yokochi; Kyoko Imanaka-Yoshida; Kenshiro Tsuda; Masato Kakeda; Ryuji Okamoto; Satoshi Fujita; Yoichiro Iwakura; Noboru Suzuki; Masaaki Ito; Kazuo Maruyama; Esteban C Gabazza; Toshimichi Yoshida; Motomu Shimaoka; Hitoshi Mizutani
Journal:  PLoS One       Date:  2014-08-13       Impact factor: 3.240

Review 3.  Molecular Therapeutics in Development for Epidermolysis Bullosa: Update 2020.

Authors:  Cristina Has; Andrew South; Jouni Uitto
Journal:  Mol Diagn Ther       Date:  2020-06       Impact factor: 4.074

Review 4.  Recent advances in understanding and managing epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Alexander Nyström
Journal:  F1000Res       Date:  2018-07-17

5.  An ex vivo RNA trans-splicing strategy to correct human generalized severe epidermolysis bullosa simplex.

Authors:  P Peking; J S Breitenbach; M Ablinger; W H Muss; F J Poetschke; T Kocher; U Koller; S Hainzl; S Kitzmueller; J W Bauer; J Reichelt; T Lettner; V Wally
Journal:  Br J Dermatol       Date:  2018-10-07       Impact factor: 9.302

Review 6.  Small molecule drug development for rare genodermatoses - evaluation of the current status in epidermolysis bullosa.

Authors:  Verena Wally; Manuela Reisenberger; Sophie Kitzmüller; Martin Laimer
Journal:  Orphanet J Rare Dis       Date:  2020-10-19       Impact factor: 4.123

Review 7.  Investigational Treatments for Epidermolysis Bullosa.

Authors:  Ping-Chen Hou; Han-Tang Wang; Stasha Abhee; Wei-Ting Tu; John A McGrath; Chao-Kai Hsu
Journal:  Am J Clin Dermatol       Date:  2021-07-22       Impact factor: 7.403

8.  Cut and Paste: Efficient Homology-Directed Repair of a Dominant Negative KRT14 Mutation via CRISPR/Cas9 Nickases.

Authors:  Thomas Kocher; Patricia Peking; Alfred Klausegger; Eva Maria Murauer; Josefina Piñón Hofbauer; Verena Wally; Thomas Lettner; Stefan Hainzl; Michael Ablinger; Johann Wolfgang Bauer; Julia Reichelt; Ulrich Koller
Journal:  Mol Ther       Date:  2017-08-24       Impact factor: 11.454

9.  Basal pharmacokinetic parameters of topically applied diacerein in pediatric patients with generalized severe epidermolysis bullosa simplex.

Authors:  Michael Ablinger; Thomas K Felder; Monika Wimmer; Roland Zauner; Peter Hofbauer; Thomas Lettner; Martin Wolkersdorfer; Florian B Lagler; Anja Diem; Johann W Bauer; Verena Wally
Journal:  Orphanet J Rare Dis       Date:  2018-11-01       Impact factor: 4.123

10.  Proinflammatory Cytokines and Antiskin Autoantibodies in Patients With Inherited Epidermolysis Bullosa.

Authors:  Giuseppina Annicchiarico; Maria Grazia Morgese; Susanna Esposito; Giuseppe Lopalco; Michele Lattarulo; Marilina Tampoia; Domenico Bonamonte; Luigia Brunetti; Antonio Vitale; Giovanni Lapadula; Luca Cantarini; Florenzo Iannone
Journal:  Medicine (Baltimore)       Date:  2015-10       Impact factor: 1.817
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.